UNIVERSITY OF SOUTH CAROLINA | COLLEGE OF NURSING
NURS 711 EXAM 1:
ADVANCED PHARMACOTHERAPIES
Comprehensive Practice Examination & Clinical Review Guide
25 HIGH-YIELD CLINICAL CASE QUESTIONS & VERIFIED ANSWERS
This comprehensive, evidence-based study guide is engineered specifically for advanced
practice registered nursing (APRN) students enrolled in NURS 711. It provides high-yield
foundational domain summaries, clinical decision-making frameworks,
pharmacokinetics/pharmacodynamics mastery, and board-style multiple-choice case
studies. Designed to evaluate advanced knowledge in therapeutic drug monitoring, drug-
drug interactions, pharmacogenomics, and organ dysfunction dosage adjustments across
primary and acute care environments.
MAIN FEATURES & CORE CONTENT DOMAINS
Domain I: Pharmacokinetics & Pharmacodynamics: CYP450 enzyme kinetics, volume of
distribution, clearance, zero vs. first-order elimination, and therapeutic index.
Domain II: Autonomic & Cardiovascular Pharmacology: RAAS blockade, beta-blocker
selectivity, antiarrhythmics, advanced anticoagulation, and heart failure GDMT.
Domain III: Neuro-Psychiatric Pharmacotherapy: SSRIs/SNRIs, atypical antipsychotics,
mood stabilizers, black box warnings, and serotonin toxicity.
Domain IV: Endocrine & Metabolic Agents: SGLT2 inhibitors, GLP-1 RAs, complex insulin
regimens, thyroid replacement, and adrenal therapeutics.
Domain V: Antimicrobial Stewardship & Patient Safety: Beta-lactams, fluoroquinolone
toxicity, vancomycin AUC monitoring, and renal dosing modifications.
Academic Year 2026 Edition | Graduate Nursing Advanced Pharmacology Series
Designed for A4 Printing, PDF Conversion, and Interactive Board Review
NURS 711 Exam 1: Advanced Pharmacotherapies (2026) Page 1
,NURS 711 Exam 1: Advanced Pharmacotherapies (2026) Page 2
, TABLE OF CONTENTS & STUDY GUIDE OVERVIEW
1. Domain Review I: Pharmacokinetics & Pharmacodynamics Page 2
2. Domain Review II: Autonomic & Cardiovascular Pharmacology Page 2
3. Domain Review III: Neuro-Psychiatric Pharmacotherapy Page 3
4. Domain Review IV: Endocrine & Metabolic Agents Page 3
5. Domain Review V: Antimicrobial Stewardship & Safety Page 3
6. Board-Style Practice Examination Bank (Questions 1 – 25) Page 4
7. High-Yield Reference Guide & Clinical Monitoring Table Page 10
CLINICAL DECISION-MAKING & EXAM STRATEGY
This exam guide emphasizes advanced clinical application rather than simple rote memorization. APRNs must assess
clinical scenarios through a physiological lens: recognizing how drug clearance changes with renal/hepatic impairment,
identifying subtle signs of drug toxicity, and selecting guideline-directed medical therapy (GDMT) tailored to patient co-
morbidities. For every question in this bank, thoroughly examine the green rationale to understand why alternative
choices are clinically suboptimal or unsafe.
DOMAIN REVIEW HIGHLIGHTS
DOMAIN I: PHARMACOKINETICS & PHARMACODYNAMICS
CYP450 Enzyme Kinetics: Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, grapefruit
juice) dramatically raise concentrations of substrate drugs (e.g., tacrolimus, simvastatin), increasing toxicity risks.
Inducers (e.g., rifampin, carbamazepine, St. John's Wort) decrease substrate drug efficacy.
Steady State & Half-Life ($t_{1/2}$): Steady state is achieved after approximately 4 to 5 half-lives of regular
dosing, independent of the dose magnitude. Elimination rate in first-order kinetics is proportional to drug
concentration.
DOMAIN II: AUTONOMIC & CARDIOVASCULAR PHARMACOLOGY
RAAS Blockade & Sacubitril/Valsartan: Switching from an ACE inhibitor to an ARNI requires a strict 36-hour
washout period to prevent severe, life-threatening angioedema caused by cumulative bradykinin accumulation.
Beta-Blocker Selectivity: Cardioselective beta-1 blockers (e.g., metoprolol succinate, atenolol, bisoprolol) are
preferred in patients with reactive airway disease (asthma/COPD). Non-selective agents (propranolol, carvedilol,
labetalol) can precipitate bronchospasm.
NURS 711 Exam 1: Advanced Pharmacotherapies (2026) Page 3
NURS 711 EXAM 1:
ADVANCED PHARMACOTHERAPIES
Comprehensive Practice Examination & Clinical Review Guide
25 HIGH-YIELD CLINICAL CASE QUESTIONS & VERIFIED ANSWERS
This comprehensive, evidence-based study guide is engineered specifically for advanced
practice registered nursing (APRN) students enrolled in NURS 711. It provides high-yield
foundational domain summaries, clinical decision-making frameworks,
pharmacokinetics/pharmacodynamics mastery, and board-style multiple-choice case
studies. Designed to evaluate advanced knowledge in therapeutic drug monitoring, drug-
drug interactions, pharmacogenomics, and organ dysfunction dosage adjustments across
primary and acute care environments.
MAIN FEATURES & CORE CONTENT DOMAINS
Domain I: Pharmacokinetics & Pharmacodynamics: CYP450 enzyme kinetics, volume of
distribution, clearance, zero vs. first-order elimination, and therapeutic index.
Domain II: Autonomic & Cardiovascular Pharmacology: RAAS blockade, beta-blocker
selectivity, antiarrhythmics, advanced anticoagulation, and heart failure GDMT.
Domain III: Neuro-Psychiatric Pharmacotherapy: SSRIs/SNRIs, atypical antipsychotics,
mood stabilizers, black box warnings, and serotonin toxicity.
Domain IV: Endocrine & Metabolic Agents: SGLT2 inhibitors, GLP-1 RAs, complex insulin
regimens, thyroid replacement, and adrenal therapeutics.
Domain V: Antimicrobial Stewardship & Patient Safety: Beta-lactams, fluoroquinolone
toxicity, vancomycin AUC monitoring, and renal dosing modifications.
Academic Year 2026 Edition | Graduate Nursing Advanced Pharmacology Series
Designed for A4 Printing, PDF Conversion, and Interactive Board Review
NURS 711 Exam 1: Advanced Pharmacotherapies (2026) Page 1
,NURS 711 Exam 1: Advanced Pharmacotherapies (2026) Page 2
, TABLE OF CONTENTS & STUDY GUIDE OVERVIEW
1. Domain Review I: Pharmacokinetics & Pharmacodynamics Page 2
2. Domain Review II: Autonomic & Cardiovascular Pharmacology Page 2
3. Domain Review III: Neuro-Psychiatric Pharmacotherapy Page 3
4. Domain Review IV: Endocrine & Metabolic Agents Page 3
5. Domain Review V: Antimicrobial Stewardship & Safety Page 3
6. Board-Style Practice Examination Bank (Questions 1 – 25) Page 4
7. High-Yield Reference Guide & Clinical Monitoring Table Page 10
CLINICAL DECISION-MAKING & EXAM STRATEGY
This exam guide emphasizes advanced clinical application rather than simple rote memorization. APRNs must assess
clinical scenarios through a physiological lens: recognizing how drug clearance changes with renal/hepatic impairment,
identifying subtle signs of drug toxicity, and selecting guideline-directed medical therapy (GDMT) tailored to patient co-
morbidities. For every question in this bank, thoroughly examine the green rationale to understand why alternative
choices are clinically suboptimal or unsafe.
DOMAIN REVIEW HIGHLIGHTS
DOMAIN I: PHARMACOKINETICS & PHARMACODYNAMICS
CYP450 Enzyme Kinetics: Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, grapefruit
juice) dramatically raise concentrations of substrate drugs (e.g., tacrolimus, simvastatin), increasing toxicity risks.
Inducers (e.g., rifampin, carbamazepine, St. John's Wort) decrease substrate drug efficacy.
Steady State & Half-Life ($t_{1/2}$): Steady state is achieved after approximately 4 to 5 half-lives of regular
dosing, independent of the dose magnitude. Elimination rate in first-order kinetics is proportional to drug
concentration.
DOMAIN II: AUTONOMIC & CARDIOVASCULAR PHARMACOLOGY
RAAS Blockade & Sacubitril/Valsartan: Switching from an ACE inhibitor to an ARNI requires a strict 36-hour
washout period to prevent severe, life-threatening angioedema caused by cumulative bradykinin accumulation.
Beta-Blocker Selectivity: Cardioselective beta-1 blockers (e.g., metoprolol succinate, atenolol, bisoprolol) are
preferred in patients with reactive airway disease (asthma/COPD). Non-selective agents (propranolol, carvedilol,
labetalol) can precipitate bronchospasm.
NURS 711 Exam 1: Advanced Pharmacotherapies (2026) Page 3
